Loading
A phase 2 trial of serplulimab, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by RenJi Hospital, now recruiting.
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) is a phase 2, interventional study registered as NCT07283692 by RenJi Hospital, with a registry enrolment figure of 46 participants, started 2026-03-01 and due to reach its primary completion in 2026-12. Interventions recorded: Serplulimab; Paclitaxel; Carboplatin. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Histologically confirmed triple negative breast cancer (ER\<10%, PR\<10%, and HER2 negative)". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Platinum agents and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Platinum agents and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Platinum agents and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Platinum agents and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Platinum agents and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Platinum agents and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Paclitaxel / nab-paclitaxel, Platinum agents and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/